Laboratory Corp. of America Holdings

As of July 25, 2025, Laboratory Corp. of America Holdings is considered very expensive with a P/E ratio of 28 and an EV to EBITDA of 14.82, despite a strong recent return of 20.86%, as its long-term performance lags behind the S&P 500 and its peers.

As of May 28, 2025, the technical trend has shifted to bullish, supported by strong indicators like bullish MACD and moving averages, with overall momentum suggesting a robust bullish outlook.

As of November 9, 2023, Laboratory Corp. of America Holdings is considered very expensive and overvalued, with a P/E ratio of 28, an EV to EBITDA ratio of 14.82, a modest ROE of 9.28%, and a low dividend yield of 1.17%.

As of March 2022, the management team of Laboratory Corp. of America Holdings includes President and CEO Adam Schechter, with Peter Neupert as the Lead Independent Director and independent directors Kerrii Anderson, Jean-Luc Belingard, Jeffrey Davis, and D. Gary Gilliland.

Laboratory Corporation of America Holdings is a mid-cap life sciences company in the healthcare diagnostics sector, with recent net sales of $3.345 billion and a net profit of $213 million. Key metrics include a P/E ratio of 28.00, a dividend yield of 1.14%, and a market capitalization of approximately $21.72 billion.

As of Jun 18, Laboratory Corp. of America Holdings has a market capitalization of $21.72 billion, with net sales of $13.18 billion and a net profit of $731.80 million for the latest four quarters.